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Background: AZD9164 has demonstrated potential as an inhaled, long-acting, muscarinic antagonist (LAMA)
bronchodilator. However, in patients with COPD, but not in healthy subjects, a transient initial drop in FEV1 was
observed following inhalation of nebulised doses of AZD9164 in citrate buffer.
Two additional studies were conducted to further assess the safety and tolerability of multiple ascending doses
of AZD9164 in 27 white and 18 Japanese healthy subjects and in 4 patients with COPD. In these studies,
AZD9164 was inhaled via Turbuhaler™.
Methods: These were Phase I, randomised, double-blind, placebo-controlled, multiple ascending dose (MAD)
studies conducted in Sweden and UK. Healthy subjects (mean age 25.9 yrs) and patients with COPD (mean age
66 yrs, mean post-bronchodilator FEV1 60.1% predicted normal value) were randomised 2:1 to active treatment
(400, 1000 or 2800 μg delivered doses of AZD9164) or placebo.
Results: No safety or tolerability concerns were identified in the healthy subjects at doses up to and including
2800 μg and both studies confirmed the bronchodilator effect of AZD9164. However, the first 3 patients in the
COPD cohort who received AZD9164 (1000 μg) experienced a transient fall in FEV1 5 to 15 minutes after
inhalation of AZD9164 while the patient receiving placebo did not. The study safety review process then
resulted in cessation of further activities on AZD9164. Retrospective analysis showed that two healthy subjects
had also had transient falls in FEV1 shortly after inhalation of AZD9164 400 and 2800 μg respectively, although
neither reported any related respiratory symptoms or other AEs.
Conclusions: These results show that transient paradoxical bronchoconstriction can occur in some healthy
subjects, in addition to patients with COPD, following inhalation of AZD9164 and that the citrate buffer used in
the nebulised formulation cannot have been the only cause of the drop in FEV1 in previous studies. As
preclinical data do not provide an explanation, the reasons for this brief post-dose drop in FEV1 remain unclear.
However, these results highlight the importance of monitoring lung function immediately post-dose when
investigating novel inhaled treatments, even when a rapid onset of effect is not expected.
Trial registration: Clinicaltrials.gov NCT01016951 and NCT01096563.
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Chronic obstructive pulmonary disease (COPD), is globally
a major and growing cause of morbidity and mortality
[1,2]. COPD is characterised by progressive airflow limita-
tion that is not fully reversible and is associated with
neutrophil-mediated airway inflammation [3]. Current
first line treatment options include long- and short-acting
inhaled bronchodilators, which have little or no effect on
the continuing decline in lung function. Monotherapy
with inhaled glucocorticosteroid therapy is less effective in
COPD than it is in asthma, which may be due to the
differing inflammatory processes involved [1].
Long-acting bronchodilators, whether administered
twice-daily, such as the β2-agonists formoterol and salme-
terol and the recently approved muscarinic antagonist
aclidinium, or once-daily, such as indacaterol, tiotropium
and the recently approved olodaterol, vilanterol, glyco-
pyrronium and umeclidinium, are the mainstay of COPD
treatment. Other long-acting, once-daily bronchodilators
are also in late stage development, including abediterol.
The muscarinic antagonist tiotropium, in particular, has
become well established as an effective once-daily bron-
chodilator for COPD over the past decade, with safety and
efficacy demonstrated in large scale trials lasting up to
three years. Tiotropium does, however, cause the anti-
cholinergic side effect of dry mouth in 6–16% of patients
with COPD [4-8]. With the aim of finding an alternative
with an improved therapeutic index relative to tiotropium,
a development program for a novel, long-acting, inhaled
muscarinic antagonist (LAMA) bronchodilator for the
treatment of patients with COPD was initiated.
The first compound from this program to be extensively
evaluated in a clinical setting is AZD9164, a product of
a collaboration between AstraZeneca Discovery and
Pulmagen Therapeutics Limited (formerly Argenta Discov-
ery Limited). In vitro, AZD9164 is a potent, competitive
antagonist at the human, rat, guinea pig and dog muscar-
inic M3 receptor with similar potency at human M1, M2,
M4 and M5 receptors. In vivo, AZD9164 is a potent antag-
onist against methacholine-induced bronchoconstriction
in anaesthetised guinea pigs and has a much longer
duration of action than ipratropium (>12 vs. 4 h) in this
model. Preclinical safety pharmacology, pharmacokinetics
(PK) and toxicology studies of AZD9164 revealed no sig-
nificant adverse findings that would preclude studies in
humans. AZD9164 demonstrated an improved therapeutic
index in guinea pig models of lung (methacholine-induced
bronchoconstriction) vs systemic (pilocarpine-induced
salivation) muscarinic antagonist effects. These pre-clinical
studies indicated that AZD9164 is a potent, long-acting
muscarinic antagonist (LAMA), and suitable for further
assessment in clinical studies.
An initial single ascending dose (SAD) study in 48
healthy human subjects (ClinicalTrials.gov IdentifierNCT00847249) established the safety and tolerability
of AZD9164 at lung deposited doses ranging from 4 to
1940 μg, and indicated a bronchodilating effect at the
higher doses (≥700 μg). In a subsequent single dose
crossover study in 28 patients with COPD, all tested
doses of AZD9164 (100 μg, 400 μg and 1200 μg lung
deposited doses) resulted in statistically significant
increases in peak, trough and 24-h average FEV1 versus
placebo [9]. The bronchodilator effect of AZD9164
400 μg was shown to be superior to tiotropium 18 μg
in this study [9]. However, the study also indicated a
transient initial, dose-dependent drop in FEV1 following
nebulisation [9]. In both studies, AZD9164 was admin-
istered dissolved in citrate buffer and inhaled via nebu-
lisation. The two studies described in this paper were
conducted to further assess the safety and tolerability
of AZD9164 after administration of multiple ascending
doses (MAD) in healthy white subjects and in patients
with COPD (NCT01016951; GMAD study) and in healthy
Japanese subjects (NCT01096563; JMAD study). In these
studies, AZD9164 was administered in the morning as a
citrate-free dry powder via aTurbuhaler™.
Objectives
The present cohort with COPD patients was added to the
original GMAD study protocol because the earlier COPD
study had revealed a transient dose-dependent decrease
in FEV1 that occurred 15 minutes after inhalation of
AZD9164 but not after placebo or tiotropium. In contrast,
no such effects had been seen in the single ascending dose
(SAD) study in healthy subjects, which had involved even
higher doses of AZD9164 and the same type of citrate
buffer. However, the first FEV1 measurement was taken
at 90 minutes post-dose in the SAD study, so that small
transient drops in FEV1 that occurred before this time
would not have been detected. The patients with COPD
in the single-dose cross-over study were not exposed to
the citrate buffer when given tiotropium or placebo. It was
therefore unclear whether the decrease in FEV1 with
AZD9164 was due to AZD9164 or to the citrate buffer in
the nebuliser solution, the quantities of which increased in
line with the dose of AZD9164. The present studies were
designed to resolve these conflicting findings and to fur-
ther assess the pharmacokinetic and pharmacodynamic
profiles of AZD9164 by administering AZD9164 as a
citrate-free dry powder via Turbuhaler™.
Methods
Study objectives
The primary objectives of the two MAD studies were to
investigate the safety and tolerability of inhaled AZD9164
delivered via Turbuhaler™ in healthy white and Japanese
subjects and also, in the GMAD study, in patients with
COPD.
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the pharmacokinetic (PK) profile and the pharmacody-
namic (PD) effects of AZD9164 inhaled via Turbuhaler™
and to establish whether AZD9164 as a dry powder
formulation is associated with bronchoconstriction in
subjects with COPD. The COPD cohort was added to the
original study protocol to provide additional data in
support of this objective.
Study designs
The GMAD study was conducted at two centres in
Sweden, while the JMAD study was conducted at a sin-
gle centre in the UK. Both were Phase I, randomised,
double-blind, placebo-controlled studies. They were con-
ducted according to the Declaration of Helsinki and Good
Clinical Practice guidelines and the AstraZeneca policy on
Bioethics. Independent ethics committees approved the
study protocols, subject information and consent forms.
The GMAD study was approved by the independent cen-
tral Ethics Committee in Stockholm, Vetenskapsrådet, 103
78 Stockholm, Sweden. The JMAD study was approved by
the Plymouth Independent Research Ethics Committee
(PIREC), Tamar Science Park, Plymouth, UK. All subjects
gave written informed consent. The first subject was en-
rolled in the GMAD study on 16 December 2009 and the
last subject last visit was on 18 June 2010. In the JMAD
study, the first subject was enrolled on 16 April 2010 and
the last subject last visit was on 4 June 2010. Subjects were
resident in the clinic from Day 1 to Day 17 of the study
period.
Due to the exploratory nature of these studies the
sample sizes were not based on formal statistical con-
siderations. The sample sizes were based on experience
from previous similar Phase I studies with other com-
pounds. In both MAD studies, the healthy subjects
were randomised 2:1 to active treatment or placebo in
three cohorts of 9 subjects. The randomisation scheme
was produced by AstraZeneca R&D using the global
randomisation system GRand. Subjects were allocated
to AZD9164 or placebo using consecutive randomisation
codes (subject numbers), so for cohorts 1 to 3, numbers
began with 101, 201 and 301. The planned doses of
AZD9164 were 400 μg delivered dose inhaled via
Turbuhaler™ in cohort 1, 1000 μg in cohort 2 and 2800 μg
in cohort 3. This equated to lung deposited doses of
approximately 200, 600 and 1500 μg, according to in vitro
batch testing of the Turbuhaler™ prior to starting the stud-
ies. Each subject received a single dose of AZD9164 or
placebo on Day 1 and subsequent doses once daily be-
tween Day 4 and Day 15 (Figure 1). The initial single
dose on Day 1 was followed by a wash-out period of
72 h to determine single-dose PK.
The studies were double-blind with regard to treatment
(AZD9164 or placebo) at each dose level. Only theAstraZeneca personnel carrying out the labelling and
packaging of study drug and analysing the PK samples
had access to the randomisation list. Individual treatment
codes, indicating the treatment randomisation for each
randomised subject, were available to the investigators or
pharmacists at the study centre. Individual sealed subject
codes (one for each subject) with instructions for code
breaking were provided to the Principal Investigators. The
treatment code was not to be broken except in medical
emergencies when the appropriate management of the
subject required knowledge of the treatment randomisa-
tion. The Principal Investigators, after confirming eligibility
and obtaining informed consent, ensured that each poten-
tial subject was assigned a unique enrolment number and
a unique randomisation code (subject number). Study
nurses primed all inhalers prior to first use.
After the last dose for each cohort, a Safety Review
Committee (SRC) evaluated all available data in a blinded
manner with the possibility of un-blinding if necessary,
and based on this determined the subsequent dose. Each
subject participated in 1 cohort only. The study design
therefore allowed a gradual escalation of dose with in-
tensive safety monitoring between each dose level to
ensure the safety of the subjects. In both studies, a
range of stopping criteria was pre-determined both for
individual subjects/patients and for the study as a whole.
These criteria included serious or non-tolerable adverse
events, clinically significant changes in laboratory values
or other safety parameters, pre-defined changes in cardiac
function such as QTc prolongation (defined as QTcF >
500 ms, or an increase of QTcF >60 ms above baseline
to a value >480 ms) and reaching pre-defined maximal
exposure levels (total Cmax and/or AUC of 48 nM and/
or 158 nM*h, respectively on day 15). In view of the fall
in FEV1 seen in the previous study, the discontinuation
criterion ‘Fall in FEV1 ≥ 30% compared with the pre-dose
value on the same day within 4 h after administration of
investigational product’ was added to the original protocol
in relation to individuals within the study. The related
overall study discontinuation criterion was ‘Two or more
subjects, who receive AZD9164, have other clinically
significant changes in laboratory values or other safety
parameters’.
In another addition to the original protocol, nine COPD
patients were to be randomised 2:1 to active treatment or
placebo in cohort 4 of the GMAD study. These patients
were to receive the 1000 μg mid dose given to healthy
subjects for 13 consecutive days with no washout follow-
ing the first dose (Figure 1).
Study subjects
All subjects in these studies had to have the ability to use
the Turbuhaler™ correctly and to provide informed con-
sent and have veins suitable for repeated venepuncture or
Figure 1 Flow chart of study designs – GMAD, JMAD and GMAD COPD cohort.
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contraception from the first day of dosing until 3 months
after the last dose of study medication (no female subjects
were enrolled except in the GMAD COPD cohort).
In the GMAD study, inclusion criteria for healthy
subjects included age 18–45 years, body mass index
(BMI) 18–30 kg/m2 and weight 50–100 kg. For the
COPD cohort, male or female patients were to be aged
over 40 years, with a BMI 18–32 kg/m2, weight 50–100 kg
and to have had a clinical diagnosis of COPD (GOLD cri-
teria) for > 1 year at enrolment, with a post-bronchodilator
FEV1 40–80% of the predicted normal value and post-
bronchodilator FEV1/FVC <70%. All were to be current or
ex-smokers with a smoking history of ≥10 pack years and
to have had a recent (<9 months) chest radiograph
showing no pathological changes that would make them
unsuitable for inclusion. Female patients were to have
negative pregnancy tests at screening and on admission
to the unit and to have no child-bearing potential, as
confirmed by investigator assessment during screening.
In the Japanese study, inclusion criteria included age
20–45 years, BMI 18–27 kg/m2 and weight 50–85 kg.
All of the subject’s parents and grandparents had to be
Japanese and the subject must have been born in Japan,
have a valid Japanese passport and have lived outside
Japan for no more than 5 years.
Exclusion criteria for all studies included history of any
clinically significant disease or disorder, or indications of
such conditions or of drug or alcohol abuse during screen-
ing, that could put subjects or patients at risk by participa-
tion in the study or interfere with absorption, distribution,
metabolism or excretion of drugs or otherwise affect study
results. A family history or presence of glaucoma or symp-
toms of narrow-angle glaucoma such as headache, seriouseye pain or halo phenomena in the evening or at night
were also grounds for exclusion from the studies. Intake
of grapefruit, Seville oranges or related products within
7 days of first administration of study medication was an-
other exclusion criterion. For the COPD patients, a COPD
exacerbation or treatment with systemic glucocorticoster-
oids (GCS) for any indication within 30 days of the first
visit, history of arrhythmia, heart block or other ECG
abnormalities, urinary retention or bladder neck ob-
struction or need for long-term oxygen therapy and/or
saturation <92% were additional grounds for exclusion.
With the exception of inhaled β2-agonists, use of medica-
tions that prolong the QT/QTc interval such as certain
antihistamines, anti-arrhythmics, tricyclic antidepressants
and monoamine oxidase inhibitors was not permitted for
the COPD patients. Use of short-acting β2-agonists and
use of inhaled corticosteroids (ICS) at a stable dose by the
COPD patients was permitted during the study period.
Use of long-acting β2-agonists, alone or in combination
with inhaled corticosteroids and use of long-acting and
short-acting muscarinic antagonists were not permitted.
The GMAD study was conducted by Quintiles at the
Berzelius Clinical Research Centre, Linköping, Sweden
and Quintiles Hermelinen, Luleå, Sweden, while the JMAD
study was conducted by Richmond Pharmacology Ltd at St
George’s University of London, UK.
The demographic and key baseline characteristics of
the healthy subjects and COPD patients are summarised
in Table 1. Figure 2 is a CONSORT patient flow diagram
for the studies.
Materials
The investigational product was formulated at AstraZeneca
R&D, Södertälje, Sweden and supplied as fully prepared
Table 1 Study demographics
Placebo AZD9164 Total
GMAD, healthy subjects n = 9 400 μg n = 6 1000 μg n = 6 2800 μg n = 6 n = 27
Age (yrs) Mean 26 21 23 22 23
SD 6 1 3 2 4
aBMI (kg/m2) Mean 23.1 23.4 21.7 21.6 22.5
SD 1.7 1.8 2.2 1.1 1.8
aWeight (kg) Mean 73.8 80.3 70.7 70.0 73.7
SD 6.8 8.1 7.4 4.7 7.6
JMAD, healthy subjects n = 6 400 μg n = 6 1000 μg n = 6 – n = 18
Age (years) Mean Mean 29.8 29.0 27.5 – 28.8
SD 4.9 4.0 3.4 – 4.0
aBMI (kg/m2) Mean 21.0 20.7 20.6 – 20.8
SD 1.2 2.3 1.4 – 1.6
aWeight (kg) Mean 61.3 63.6 61.4 – 62.1
SD 4.3 7.7 5.5 – 5.8
GMAD, COPD patients n = 1 – 1000 μg n = 3 – n = 4
Age (yrs) Mean 71 – 64 – 66
SD NC – 7 – 6
aBMI (kg/m2) Mean 23.0 – 27.8 26.6
SD NC – 4.0 4.0
aWeight (kg) Mean 77.1 – 73.9 – 74.7
SD NC – 8.1 – 6.8
bFEV1 (L) Mean 1.62 – 1.48 – 1.52
SD NC – 0.53 – 0.43
bFEV1 (% predicted) Mean 48.80 – 64.63 – 60.67
SD NC – 17.82 – 16.57
bFEV1/FVC (%) Mean 31.95 – 49.45 – 45.08
SD NC – 5.66 – 9.90
Smoking history (%) Current 1 (100) – 2 (67) 3 (75)
Former 0 (0) 1 (33) 1 (25)
Years since diagnosis Mean 5 10 9
SD NC 9 8
aAt enrolment.
bFEV1 and FVC measurements were made after inhalation of Atrovent® (post-bronchodilator).
BMI Body mass index, NC Not calculable.
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to use. The dry powder for inhalation within each Tur-
buhaler™ was a mixture of AZD9164 and lactose mono-
hydrate for inhalation. The placebo Turbuhaler™ was
identical in appearance but contained lactose monohy-
drate powder only.
Assessments
Safety assessments included recording of AEs, physical
examination and changes in laboratory variables, vital
signs (BP, pulse, body temperature), ECG and lung func-
tion (FEV1 and FVC). AEs were assessed throughout the
treatment period and follow-up period. Blood sampleswere taken daily and telemonitoring was continuous
during the residential period of the study. On Days 1
and 15, a 12-lead ECG was recorded at regular intervals
from 30 minutes up to 48 h post-dose. Blood samples
for PK measurements and laboratory values were taken
pre-dose and at 5, 15, 30, 60 and 90 minutes and 2, 4, 6,
8, 12, 24, 36, 48, 72 and 120 h post-dose on Days 1 and
15. Pulse and BP were recorded pre-dose and at 30 min,
2, 4, 8, 12 and 24 h post-dose on days 1 and 15 and at
1 h post-dose on days 4 and 9. Lung function was re-
corded pre-dose and at 5, 15, 30 and 60 min and 2, 4, 12
and 24 h post-dose on Days 1 and 15, pre-dose and at 5,
15, 30 and 60 min and 2 h post-dose on days 4, 5 and 8,
Figure 2 CONSORT patient flow diagram.
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9–14 for the healthy subjects in the GMAD and JMAD
studies. For the GMAD COPD cohort, lung function
was to be recorded pre-dose and at 5, 15, 30 and 60 min
and 2, 4, 12 and 24 h post-dose on days 1 and 13, pre-
dose and at 5, 15, 30 and 60 min and 2 h post-dose on
days 2, 3 and 6 and pre-dose and at 15 min post-dose
on days 4, 5 and 7–12.
The PK profile of AZD9164 was assessed in terms of
maximum plasma concentration (Cmax), time to reach
Cmax (tmax), terminal half-life (t1/2), area under the
plasma-concentration time curve (AUC; AUC0–∞ for
first dose and AUC0–24 for last dose), dose-normalised
Cmax and AUC (Cmax/Dose, AUC/Dose) and accumula-
tion ratio (Rac = AUC0–24 for last dose/AUC0–24 for first
dose).
The PD effects of AZD9164 were assessed by evaluating
FEV1, FVC, supine BP, heart rate, pulse, QT interval with
Fridericia’s correction (QTcF) over the first 4 h following
first and last drug administration respectively (Days 1 and
15). Average effect (Eav) and maximum effect (Emax) over
the first 4 h were calculated and recorded for all PD pa-
rameters except diastolic BP, for which Eav and minimum
effect (Emin) were calculated and recorded. Lung function
(FEV1) was assessed from 0–4 h post-dose to ensure that
Emax was recorded.
All statistical and PK analyses were performed by
Quintiles AB, Global Phase I Services, Uppsala, Sweden.
All statistical calculations were performed with the SAS®
software version 9.2. Pharmacokinetic parameters werederived using standard non-compartmental methods
with WinNonlin® Professional Version 5.2. The safety
analysis sets included all subjects who received at least
one dose of randomised investigational product and had
data collected post-dose. The PK analysis sets included
all subjects who received at least 1 dose of AZD9164
and from whom evaluable PK data appropriate for the
analysis of interest were available. The PD analysis sets
included all subjects who received at least 1 dose of ran-
domised investigational product and for whom evaluable
PD data appropriate for the analysis of interest were
available. The as-treated principle was applied to all
evaluations.
Results
In the GMAD study, a total of 27 white healthy male
subjects, aged 19 to 39 years, were randomised; all but
three completed the study and received 13 administra-
tions of AZD9164 or placebo. Of the three discontinu-
ations, two subjects had received placebo and one had
received AZD9164. One male and 3 female patients
with COPD were included in a separate cohort. In the
JMAD study, 18 Japanese healthy male subjects, aged
24–38 years, were randomised. All subjects in the first
two cohorts completed the study and received all doses
according to the study plan but the study was halted
before the third cohort received the highest planned
dose level of 2800 μg. Overall, the treatment groups
were well balanced and comparable with respect to
demographic characteristics.
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There were no safety or tolerability concerns identified
in healthy subjects at doses up to and including 2800 μg.
In the GMAD study, there were no deaths recorded,
but there were two discontinuations due to AE (DAE); both
occurred in the placebo group. One was due to a serious
adverse event (SAE), a brief asymptomatic ventricular
tachycardia, which occurred on Day 5 almost 3 h after
dose administration. The other DAE (due to pyrexia and
diarrhoea) occurred on Day 10, between 11 and 13 h
post-dose. Calicivirus RNA was subsequently detected
in a faeces sample from this subject.
In the GMAD study, a total of 40 AEs was reported by
the 18 healthy subjects who received AZD9164, with 31
AEs reported by the 9 who received placebo. The frequency
of AEs was therefore greatest in the placebo-treated
subjects. The frequency of AEs was lowest in the group
receiving the lowest dose of AZD9164. A summary of
adverse events is provided in Tables 2, 3 and 4. No AE
with severe intensity was recorded. Seven AEs in the
placebo group and 1 AE in the 1000 μg and 2800 μg
group respectively were regarded to be of moderate in-
tensity. The rest were of mild intensity. The seven AEs
reported by three subjects that were assessed as causally
related to treatment with AZD9164 included dry mouth
(1 event), throat irritation (3 events), cough (2 events) and
flushing (1 event). These were all mild in intensity and
occurred only with the highest dose. Six healthy subjects
receiving AZD9164 and one subject who received pla-
cebo reported respiratory-related AEs of which the mostTable 2 Summary of frequency of adverse events across the s
Placebo
GMAD, healthy subjects n = 9 400 μg
n = 6
Any AEa 8 (88.9) 5 (83.3)
SAEsa 1(11.1) 0 (0)
DAEsa 2 (22.2) 0 (0)
Total number of AEs 31 7
JMAD, healthy subjects n = 6 400 μg
n = 6
Any AEa 3 (50.0) 6 (100.0)
SAEsa 0 (0) 0 (0)
DAEsa 0 (0) 0 (0)
Total number of AEs 3 10
GMAD, COPD patients n = 1
Any AEa 1 (100)
SAEsa 0 (0)
DAEsa 0 (0)
Total number of AEs 1
aNumber (%) of patients who had an AE in each category. Subjects with multiple evcommon was throat irritation (Table 3). Five of these
respiratory-related AEs (throat irritation: 3 events and
cough: 2 events) were reported by 2 subjects in the highest
dose group (2800 μg). All of these events occurred in close
association with either first or second dose and were
assessed as causally related to treatment by the investiga-
tor. In the JMAD study, there were no deaths, SAEs or
DAEs reported. All AEs were of mild intensity. Thirteen
of the 18 Japanese subjects reported 20 adverse events
after receiving AZD9164 or placebo. Six of these subjects
received the 400 μg dose and four received the 1000 μg
dose. There was no increase in adverse events or in sub-
jects reporting AEs with increasing doses. Four of the AEs
were considered to be causally related to the study drug in
each of the 400 μg and 1000 μg dose cohorts. The most
common AE was localised rash, associated with the ECG
tabs in three of the six cases. Two subjects reported the re-
spiratory AE of cough following treatment with AZD9164
on Day 1. One of these subjects also had an associated
transient 11% decrease in FEV1 at five and 15 minutes
after dosing (400 μg), and the other had a 20% reduction
in FEV1 at five minutes post-dose (1000 μg). Both subjects
coughed immediately after inhalation.
There were no clinically important patterns in la-
boratory test results, vital signs or ECG parameters with
increasing doses of AZD9164. Of particular interest, given
the known potential for muscarinic antagonists to affect
the QT interval, there were no QTcF values exceeding
450 ms and no notable changes from baseline in QTcF
after administration of AZD9164. There were no markedtudies
AZD9164
1000 μg 2800 μg Total (%)
n = 6 n = 6 n = 27
6 (100) 6 (100) 25 (92.6)
0 (0) 0 (0) 1 (3.7)
0 (0) 0 (0) 2 (7.4)
18 15 71
1000 μg Total (%)
n = 6 n = 18
4 (66.7) 13 (72.2)
0 (0) 0 (0)
0 (0) 0 (0)
7 20
n = 3 n = 4
3 (100) 4 (100)
0 (0) 0 (0)
1 (33.3) 1 (25.0)
8 9
ents in the same category are counted only once in each category.
Table 3 Summary of patients affected by respiratory-related adverse events
AEs classified as Respiratory, Thoracic and/or Mediastinal Disorders
Placebo AZD9164
GMAD, healthy subjects n = 9 400 μg 1000 μg 2800 μg Total (%)
n = 6 n = 6 n = 6 n = 27
Throat irritation 1 (11.1) 0 (0) 1 (16.7) 2 (33.3) 4 (14.8)
Oropharyngeal pain 0 (0) 1 (16.7) 2 (33.3) 0 (0) 3 (11.1)
Cough 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (3.7)
Dyspnoea 0 (0) 0 (0) 1 (16.7) 0 (0) 1 (3.7)
JMAD, healthy subjects n = 6 400 μg 1000 μg Total (%)
n = 6 n = 6 n = 18
Cough 0 (0) 1 (16.7) 1 (16.7) 2 (11.1)
Epistaxis 0 (0) 0 (0) 1 (16.7) 1 (5.6)
Nasal mucosal disorder 0 (0) 0 (0) 1 (16.7) 1 (5.6)
Respiratory tract infection 0 (0) 0 (0) 1 (16.7) 1 (5.6)
Upper respiratory tract infection 0 (0) 1 (16.7) 0 (0) 1 (5.6)
GMAD, COPD patients n = 1 n = 3 n = 4
Dyspnoea 1 (100) 2 (66.7) 2 (50)
Cough 0 (0) 1 (33.3) 1 (25)
Table 4 Summary of adverse events causally related to treatment with AZD9164
AEs assessed as causally-related to AZD9164
Placebo AZD9164
GMAD, healthy subjects n = 9 400 μg 1000 μg 2800 μg Total (%)
n = 6 n = 6 n = 6 n = 27
Dry mouth 0 1 (16.7) 1 (3.7)
Throat irritation 0 3 (50.0) 3 (11.1)
Cough 0 2 (33.3) 2 (7.4)
Flushing 0 1 (16.7) 1 (3.7)
JMAD, healthy subjects n = 6 400 μg 1000 μg Total (%)
n = 6 n = 6 n = 18
Rash 0 1 (16.7) 1 (5.6)
Headache 0 1 (16.7) 1 (5.6)
Cough 0 1 (16.7) 1 (16.7) 2 (11.1)
Upper respiratory tract infection 0 1 (16.7) 0 1 (5.6)
Respiratory tract irritation 0 1 (16.7) 1 (5.6)
Epistaxis 0 1 (16.7) 1 (5.6)
Nasal mucosal disorder 0 1 (16.7) 1 (5.6)
GMAD, COPD patients n = 1 n = 3 n = 4
Dry mouth 0 1 (33.3) 1 (25.0)
Palpitations 0 1 (33.3) 1 (25.0)
Anxiety 0 1 (33.3) 1 (25.0)
Dyspnoea 0 2 (66.6) 2 (50.0)
Cough 0 1 (33.3) 1 (25.0)
Haematoma 0 1 (33.3) 1 (25.0)
Fatigue 0 1 (33.3) 1 (25.0)
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and healthy subjects receiving placebo in either of the
studies. There was a mean increase of 8 mmHg in average
systolic blood pressure at the 2800 μg dose compared to
placebo after the last dose in the GMAD study and a
minor mean increase in diastolic blood pressure at the
1000 μg dose compared to placebo in the JMAD study.
Effects on FEV1
Both studies provided further evidence of the bronchodi-
lating effect of AZD9164. In the GMAD study, numerical
mean increases vs placebo of up to 10% in the FEV1 Emax
were seen in the healthy subjects. The increases were
greater after repeated dosing, reaching statistical signifi-
cance after the last dose of 2800 μg. In the JMAD study,
there was a statistically significant improvement in both
average and peak FEV1 over 4 h compared to placebo after
the last doses of 400 μg and 1000 μg.
In the GMAD study, small, transient decreases in
mean FEV1 were observed on Day 1 in healthy subjects
at 15 minutes after administration of single doses of
400 μg AZD9164 (2.3% decrease), 2800 μg AZD9164
(5.5% decrease) and placebo (3.9% decrease) but not
after administration of 1000 μg AZD9164 (1.4% increase).
One healthy subject was discontinued from the GMAD
study in accordance with the FEV1 discontinuation criter-
ion (“a fall in FEV1 ≥ 30% compared with the pre-dose
value within 4 h after administration of investigational
product”). The maximum reduction in FEV1 (34%) for this
subject occurred 30 minutes after the first dose of
AZD9164 2800 μg on Day 1. This subject had no respira-
tory symptoms or any other AEs in connection with the
fall in FEV1 and his FVC remained normal. The subject
had an unusual exhalatory technique that resulted in diffi-
culty in exhaling fully and correctly into the spirometer
and his result may therefore have been an artefact. A sec-
ond healthy subject in the GMAD study had a similar
drop in FEV1 (31%) five minutes after the 6th dose of
AZD9164 400 μg. The event was not associated with any
respiratory symptoms or other AEs. A reporting error led
to this subject’s fall in FEV1 being overlooked at the time,
but the correct values were relocated retrospectively.
Although there was no clear dose-dependency for the
decrease in FEV1, the highest dose produced the largest
of the individual falls recorded.
In the JMAD study, a dose dependent initial mean de-
crease in FEV1 of 2% and 8% was observed at five minutes
following dosing with AZD9164 400 μg and 1000 μg, re-
spectively on Day 1 (Figure 3A). Five out of six subjects
showed an initial decrease in FEV1 of between 4 and 20%
in the 1000 μg group. However, increases above baseline
FEV1 value were observed at 15 minutes (400 μg) and
1 hour (1000 μg) post-dose. Mean values for FEV1 0–4 h
in healthy subjects from the GMAD and JMAD studiesafter the first and last doses are shown in Figures 3A and
3B respectively.
Pharmacokinetics
In healthy subjects, the absorption of AZD9164 from the
lung was rapid and similar between doses and study popu-
lations with a median tmax of between 5 and 15 minutes.
After Cmax, the plasma concentration-time profiles
showed a multi-phasic, mainly parallel decline with a geo-
metric mean t½ after the last dose of 166 h in the GMAD
study and 118 h in the JMAD study. The plasma concen-
trations of AZD9164 were above the lower limit of quanti-
fication (LLOQ of 10.0 pmol/L) throughout the sampling
periods i.e. 72 h after single dose and 120 h after last dose.
The geometric mean Rac after once daily dosing was 3.08
in the GMAD study and 2.77 in the JMAD study. A
summary of relevant pharmacokinetic data is provided
in Table 5.
There was no indication of dose dependency in PK in the
400 μg to 2800 μg delivered dose range in the GMAD
study. No firm conclusion could be reached regarding dose
dependency in the JMAD study (only two cohorts were
completed, at doses of 400 μg and 1000 μg of AZD9164).
Plasma samples for pharmacokinetic analysis were col-
lected from three COPD patients at 1 h, and from two
of these patients at 24 h, following inhalation of a single
dose of 1000 μg AZD9164. The plasma concentrations
at 1 h were higher in COPD patients compared to those
in healthy subjects; however the levels were within one
doubling dose (assuming dose linearity). The concentra-
tions at 24 h in COPD patients were similar to those of
the healthy subjects.
Evaluations for patients with COPD
The GMAD study was prematurely stopped after three
COPD patients had been exposed to a single dose of
AZD9164 (1000 μg) and one to placebo in the fourth
cohort. The safety review process enabled unblinding of
data for these patients which then led to the cessation
of further study activities on AZD9164.
The three COPD patients who received the 1000 μg
dose of AZD9164 experienced a fall in FEV1 of 34%, 28%
and 34%, respectively, 5 to 15 minutes after inhalation of
the first dose whereas no fall was noted for the patient
receiving placebo. (Figure 4) Two of these patients also
reported mild dyspnoea but had no other clinically relevant
symptoms. The patient with a fall in FEV1 of 34% also ex-
perienced a DAE, due to severe anxiety, palpitations of
moderate intensity and dry mouth of mild intensity. These
symptoms were coincident with the fall in FEV1 and were
assessed as causally related to study drug. In all three pa-
tients receiving AZD9164, however, FEV1 had returned to
baseline or above within one hour and remained above
baseline values at all subsequent time points to 4 h post
Figure 3 Effects of AZD9164 on mean values for FEV1 over the first 4 h after dosing. A. FEV1 0–4 h after first dose – GMAD, JMAD
combined data from healthy subjects. B. FEV1 0–4 h after last dose – GMAD, JMAD combined data from healthy subjects.
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vidual FEV1 discontinuation criterion, the study discon-
tinuation criterion “Two or more subjects, who receive
AZD9164, have other clinically significant changes in la-
boratory values or other safety parameters” was also met.
In total, there was 1 DAE and 8 AEs among the three
COPD patients who received a single dose of AZD9164
1000 μg in the GMAD study (Table 2). Three of the AEs
were mild respiratory symptoms (2 dyspnoea, 1 cough).
These were assessed by the investigator as being causallyrelated to the study drug. The patient who received
placebo also complained of dyspnoea but this was assessed
as unrelated to treatment. Subsequent analysis revealed
no clinically important abnormalities in laboratory safety
test results, ECG measurements or vital signs assessments
relating to these AEs.
Discussion
The results of the small exploratory studies reported here
indicate that the fall in FEV1 observed in COPD patients
Table 5 Summary of pharmacokinetic parameters for AZD9164 after single dose and after last dose (400 μg, 1000 and
2800 μg)
First dose Last dose
Geometric mean (CV%)
PK parameters AZD9164 400 μg 1000 μg 2800 μg 400 μg 1000 μg 2800 μg
(n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 5)
GMAD Study healthy subjects
Cmax (nmol/L) 1.32 (52.9) 3.93 (64.9) 13.3 (136.0) 1.95 (36.2) 7.47 (50.5) 16.0 (140.0)
tmax (min)
a 10.0 (5–31) 10.0 (5–16) 5.0 (5–15) 11.0 (5–31) 5.0 (5–16) 5.0 (5–6)
t½ (h) 95.1 (19.5) 137 (41.1) 72.3 (58.5) 189 (62.4) 179 (86.1) 131.0 (55.9)
AUCb 11.8 (30.1) 41.3 (62.1) 54.5 (113) 12.1 (25.0) 39.4 (42.2) 58.6 (87.8)
Cmax/dose(10-3/L) 1.53 (52.9) 1.83 (64.9) 2.21 (136.0) 2.28 (36.2) 3.47 (50.5) 2.67 (140.0)
AUC/Doseb 0.0138 (30.1) 0.0193 (62.1) 0.0092 (113) 0.0141 (25.0) 0.0184 (42.2) 0.0098 (87.8)
Rac - - - 3.23 (22.1) 3.52 (48.4) 2.47 (30.0)
JMAD Study healthy subjects
Cmax (nmol/L) 1.14 (30.8) 7.27 (47.6) - 1.83 (33.2) 6.30 (31.8) -
tmax (min)
a 15 (5–60) 5 (5–5) - 15 (5–90) 5 (5–15) -
t½ (h) 88.1 (29.7) 71.3 (11.9) - 107.3 (26.2) 130.2 (56.9) -
AUCb 12.5 (23.0) 29.4 (49.3) - 15.6 (18.7) 28.6 (40.9) -
Cmax/dose(10-3/L) 1.33 (30.8) 3.39 (47.6) - 2.13 (33.2) 2.93 (31.8) -
AUC/Doseb 0.0145 (23.0) 0.0137 (49.3) - 0.0182 (18.7) 0.0133 (40.9) -
Rac - - - 3.69 (24.4) 2.08 (25.1) -
aMedian (minimum to maximum).
bZero to infinity for single dose; 0–24 for last dose.
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content of the buffer alone. All three COPD patients
who received citrate-free AZD9164 via Turbuhaler™
experienced a significant fall in FEV1 5 to 15 minutes
after inhalation of AZD9164, while the patient receivingFigure 4 FEV1 0–4 h after initial dose – GMAD study COPD patients.placebo did not. Two of 18 healthy white subjects and 0 of
12 healthy Japanese subjects also demonstrated transient
falls in FEV1 > 30% shortly after inhalation of AZD9164.
Adverse events of a mainly respiratory nature were associ-
ated with the falls in FEV1, primarily in the COPD cohort.
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discontinued, due to these findings.
Despite preclinical assessment and subsequent re-
evaluation in the light of these findings, the reason for
the brief post-dose drop in FEV1 in some healthy subjects
and all of the patients with COPD remains unclear. The
M1, M2 and M3 receptors that have been demonstrated in
human airways appear to have different physiological
functions [10-12] The M1 receptors in airway parasympa-
thetic ganglia facilitate cholinergic neurotransmission,
which therefore indirectly enhances cholinergic broncho-
constriction. The M3 receptors on airway smooth muscle
cells, inflammatory cells and submucosal glands directly
mediate bronchoconstriction and mucus secretion. The
M2 receptors at prejunctional cholinergic nerve endings
control the release of acetylcholine and act as feedback
inhibitory receptors. One explanation for the current
findings could be that either partial agonist activity at
the M1 receptor or M2 antagonist effects could hypo-
thetically enhance cholinergic drive before the onset of
M3 antagonism to inhibit the immediate increase in
cholinergic drive. However, there was no indication from
available preclinical data that this is the explanation
for the observations with AZD9164. An additional, non-
pharmacological explanation could be that AZD9164 has
a localised irritant effect which is greater in the inflamed
lung tissue of patients with COPD than in healthy
subjects.
Paradoxical bronchospasm after inhalation of a bron-
chodilator is not a novel occurrence. A review of adverse
reaction reports for inhaled β2-selective, adrenergic-
agonist bronchodilators between 1974 and 1988 revealed
126 reports consistent with a diagnosis of paradoxical
bronchospasm associated with use of these drugs by
metered-dose inhaler, and a further 58 such reports be-
tween 1983 and 1988 for these drugs delivered by neb-
ulisation [13]. Salbutamol has been shown to cause
occupational asthma in pharmaceutical workers and
has an asthma hazard index of 0.84 on a scale of 0–1,
with a value of 0.5 or higher indicating asthmagenic
potential [14].
Paradoxical bronchoconstriction may cause a fall in FEV1
with no other symptoms or it may cause cough, wheeze
and dyspnoea and the need for use of rescue medication. It
may be caused by an adverse reaction to the drug being ad-
ministered or to the excipients, preservatives, surfactants,
stabilisers or propellants used in its delivery [15-18]. Abrupt
changes in osmolarity, temperature or pH in lung tissue
resulting from inhalation of a drug aerosol, airflow turbu-
lence, deep inhalation or expiration and repeated spirom-
etry efforts may also trigger bronchospasm [16,19,20].
Which of these factors was involved in these studies is
unclear, but the dual response to AZD9164 raises interest-
ing scientific issues which will continue to be explored.Conclusions
The initial bronchoconstrictor effect observed with
AZD9164 makes this molecule unfit for its intended
purpose. However, the experience in early clinical evalu-
ation of AZD9164 has highlighted the importance of in-
cluding early timepoint measurements of lung function
when investigating novel inhaled treatments, even when a
rapid onset of effect is not anticipated.
Endnote
aTurbuhaler™ is a trademark of the AstraZeneca group
of companies. Turbuhaler™ is a registered trademark in
Sweden and United Kingdom where the studies were
performed.
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